Clinical trials: Liver Tumor
Hepatocellular Carcinoma
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
The phase I/II, double-blind, randomized study will investigate the efficacy and safety of TACE/TAE treatment with T-ACE Oil in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT05435014
- Testing
- T-ACE Oil, Lipiodol
- Where
- 4 sites in Taiwan
- Volunteers
- 2 people
- Sponsor
- T-ACE Medical Co., Ltd
Carcinoma, Hepatocellular
INSIGHT - Post Marketing Surveillance
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment…
- Trial name
- INSIGHT (NCT00792350)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 791 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07291076
- Testing
- Pumitamig, Ipilimumab
- Where
- 67 sites in United States, Australia and 12 more
- Volunteers
- 198 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Expanding Phase III Study of Tyroserleutide for Injection
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT03516448
- Testing
- Gan Fu Le Tablets, Tyroserleutide for injection
- Volunteers
- 352 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Liver Cancer
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET1402L1-CART-cells in patients with AFP+ HCC
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- NCT03349255
- Testing
- autologous ET1402L1-CART cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Aeon Therapeutics (Shanghai) Co., Ltd.
Hepatocellular Carcinoma, Cholangiocarcinoma
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03734926
- Testing
- ZSP1241
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Hepatocellular Carinoma
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in…
- Trial name
- FLASH (NCT01636284)
- Testing
- JX-594 recombinant vaccina GM-CSF
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- Jennerex Biotherapeutics
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Bile Duct Carcinoma
- Trial name
- NCT03507998
- Testing
- CGX1321
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Curegenix Inc.
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics